The American Journal of Managed Care

ASH 2021 Recap: Real-World Evidence

Greater use of real-world data (RWD) in studying and treating hematologic malignancies promises to speed up the delivery of new therapies and create more tailored regimens for groups who have not been ...
The American Journal of Managed Care

ASH 2021 Recap: CAR T-Cell Therapy

Ongoing and new developments in chimeric antigen receptor (CAR) T-cell therapies were covered at the 63rd American Society of Hematology (ASH) annual meeting. Coming into the 2021 American Society of ...
Business Wire

Genentech to Present New Pivotal Data at ASH 2021 From Broad and Comprehensive Portfolio, Challenging Treatment Standards for People With Blood Disorders

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its extensive hematology portfolio will be ...
Business Insider

Antengene to Release Preliminary Results of Selinexor for the Treatment of Peripheral T-Cell Lymphoma and NK/T-Cell Lymphoma at the 2021 ASH Annual Meeting

SHANGHAI and HONG KONG, Nov. 9, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, ...
Business Wire

Equillium Announces Additional Patient Data at ASH 2021 Demonstrating Continued Positive and Durable Clinical Responses in Acute Graft-Versus-Host Disease Patients Treated with ...

Equillium Announces Additional Patient Data at ASH 2021 Demonstrating Continued Positive and Durable Clinical Responses in Acute Graft-Versus-Host Disease Patients Treated with Itolizumab Data from ...
Monthly Prescribing Reference

CAR-T Therapy May Improve Outcomes in Second-Line Relapsed/Refractory LBCL

In the phase 2 ZUMA-2 study, KTE-X19 CAR-T therapy showed a lasting clinical benefit and manageable side effects in relapsed/refractory mantle cell lymphoma. Researchers sought to determine whether ...
Monthly Prescribing Reference

Adding Pevonedistat to Azacitidine Does Not Improve Outcomes for Patients With MDS/CMML and AML

Peripheral blood sample MRD assessment will likely come into routine clinical use in the next few years, according to an expert who specializes in CLL. Researchers sought to determine whether adding ...